Loading…

Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy

We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progress...

Full description

Saved in:

Bibliographic Details
Published in:	Internal Medicine 2022/02/15, Vol.61(4), pp.527-531
Main Authors:	Maetani, Tomoki, Hamaguchi, Toka, Nishimura, Takafumi, Marumo, Satoshi, Fukui, Motonari
Format:	Article
Language:	English
Subjects:	Adrenal Cortex Hormones - therapeutic use Aged Antibodies, Monoclonal Biopsy Carcinoma, Non-Small-Cell Lung - pathology Case Report Chemoradiotherapy Chemoradiotherapy - methods Corticosteroids durvalumab Dyspnea Echocardiography EKG Heart diseases Humans Internal medicine irAE lung cancer Lung Neoplasms - drug therapy Magnetic resonance imaging Male Myocarditis Myocarditis - chemically induced Myocarditis - diagnosis Myocarditis - drug therapy Non-small cell lung carcinoma Respiration Small cell lung carcinoma Steroids
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23
cites	cdi_FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23
container_end_page	531
container_issue	4
container_start_page	527
container_title	Internal Medicine
container_volume	61
creator	Maetani, Tomoki Hamaguchi, Toka Nishimura, Takafumi Marumo, Satoshi Fukui, Motonari
description	We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.
doi_str_mv	10.2169/internalmedicine.7644-21
format	article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8907760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634884020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23</originalsourceid><addsrcrecordid>eNplkc2O0zAUhS0EYjoDr4AisWGTwf9ONkioAwNSgQVliawb52bqKo2LnQzq2-PQUsGwOV7c7x4f-xBSMHrNma5f-2HEOEC_w9Y7P-C10VKWnD0iCyZkXRou1GOyoDWrSp7lglymtKVUVKbmT8mFkFIIw8yCfL-Z4j300w6aElIKzsOIbbHKWoYh4Vh8OgQHsfWjT8XXyTlMqZv6_lCsI_5mf_pxUyxDHL0LKecKvi3WG4ywPzwjTzroEz4_nVfk2_t36-WHcvXl9uPy7ap0mtZj6VSjmpq5TtZSAaVcsQ5AozRUA0ppsK04Nka5ilI0jFEBqBvFdY2KNlxckTdH3_3U5D9xOIwReruPfgfxYAN4--9k8Bt7F-5tVVNjNM0Gr04GMfyYMI1255PDvocBw5QsVzpnM1yrjL58gG7DNJeRKS1kVUnKZ8PqSLkYUorYncMwaucO7cMO7dxhHuXVF38_5rz4p7QMfD4C2zTCHZ4BmCvo8X9nzayc5XTDGXQbiBYH8Qsq8Lzb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634884020</pqid></control><display><type>article</type><title>Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy</title><source>Open Access: PubMed Central</source><creator>Maetani, Tomoki ; Hamaguchi, Toka ; Nishimura, Takafumi ; Marumo, Satoshi ; Fukui, Motonari</creator><creatorcontrib>Maetani, Tomoki ; Hamaguchi, Toka ; Nishimura, Takafumi ; Marumo, Satoshi ; Fukui, Motonari</creatorcontrib><description>We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.7644-21</identifier><identifier>PMID: 34433717</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Aged ; Antibodies, Monoclonal ; Biopsy ; Carcinoma, Non-Small-Cell Lung - pathology ; Case Report ; Chemoradiotherapy ; Chemoradiotherapy - methods ; Corticosteroids ; durvalumab ; Dyspnea ; Echocardiography ; EKG ; Heart diseases ; Humans ; Internal medicine ; irAE ; lung cancer ; Lung Neoplasms - drug therapy ; Magnetic resonance imaging ; Male ; Myocarditis ; Myocarditis - chemically induced ; Myocarditis - diagnosis ; Myocarditis - drug therapy ; Non-small cell lung carcinoma ; Respiration ; Small cell lung carcinoma ; Steroids</subject><ispartof>Internal Medicine, 2022/02/15, Vol.61(4), pp.527-531</ispartof><rights>2022 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><rights>Copyright © 2022 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23</citedby><cites>FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907760/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907760/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34433717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maetani, Tomoki</creatorcontrib><creatorcontrib>Hamaguchi, Toka</creatorcontrib><creatorcontrib>Nishimura, Takafumi</creatorcontrib><creatorcontrib>Marumo, Satoshi</creatorcontrib><creatorcontrib>Fukui, Motonari</creatorcontrib><title>Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Aged</subject><subject>Antibodies, Monoclonal</subject><subject>Biopsy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Case Report</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy - methods</subject><subject>Corticosteroids</subject><subject>durvalumab</subject><subject>Dyspnea</subject><subject>Echocardiography</subject><subject>EKG</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>irAE</subject><subject>lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Magnetic resonance imaging</subject><subject>Male</subject><subject>Myocarditis</subject><subject>Myocarditis - chemically induced</subject><subject>Myocarditis - diagnosis</subject><subject>Myocarditis - drug therapy</subject><subject>Non-small cell lung carcinoma</subject><subject>Respiration</subject><subject>Small cell lung carcinoma</subject><subject>Steroids</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNplkc2O0zAUhS0EYjoDr4AisWGTwf9ONkioAwNSgQVliawb52bqKo2LnQzq2-PQUsGwOV7c7x4f-xBSMHrNma5f-2HEOEC_w9Y7P-C10VKWnD0iCyZkXRou1GOyoDWrSp7lglymtKVUVKbmT8mFkFIIw8yCfL-Z4j300w6aElIKzsOIbbHKWoYh4Vh8OgQHsfWjT8XXyTlMqZv6_lCsI_5mf_pxUyxDHL0LKecKvi3WG4ywPzwjTzroEz4_nVfk2_t36-WHcvXl9uPy7ap0mtZj6VSjmpq5TtZSAaVcsQ5AozRUA0ppsK04Nka5ilI0jFEBqBvFdY2KNlxckTdH3_3U5D9xOIwReruPfgfxYAN4--9k8Bt7F-5tVVNjNM0Gr04GMfyYMI1255PDvocBw5QsVzpnM1yrjL58gG7DNJeRKS1kVUnKZ8PqSLkYUorYncMwaucO7cMO7dxhHuXVF38_5rz4p7QMfD4C2zTCHZ4BmCvo8X9nzayc5XTDGXQbiBYH8Qsq8Lzb</recordid><startdate>20220215</startdate><enddate>20220215</enddate><creator>Maetani, Tomoki</creator><creator>Hamaguchi, Toka</creator><creator>Nishimura, Takafumi</creator><creator>Marumo, Satoshi</creator><creator>Fukui, Motonari</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220215</creationdate><title>Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy</title><author>Maetani, Tomoki ; Hamaguchi, Toka ; Nishimura, Takafumi ; Marumo, Satoshi ; Fukui, Motonari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Aged</topic><topic>Antibodies, Monoclonal</topic><topic>Biopsy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Case Report</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy - methods</topic><topic>Corticosteroids</topic><topic>durvalumab</topic><topic>Dyspnea</topic><topic>Echocardiography</topic><topic>EKG</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>irAE</topic><topic>lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Magnetic resonance imaging</topic><topic>Male</topic><topic>Myocarditis</topic><topic>Myocarditis - chemically induced</topic><topic>Myocarditis - diagnosis</topic><topic>Myocarditis - drug therapy</topic><topic>Non-small cell lung carcinoma</topic><topic>Respiration</topic><topic>Small cell lung carcinoma</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maetani, Tomoki</creatorcontrib><creatorcontrib>Hamaguchi, Toka</creatorcontrib><creatorcontrib>Nishimura, Takafumi</creatorcontrib><creatorcontrib>Marumo, Satoshi</creatorcontrib><creatorcontrib>Fukui, Motonari</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maetani, Tomoki</au><au>Hamaguchi, Toka</au><au>Nishimura, Takafumi</au><au>Marumo, Satoshi</au><au>Fukui, Motonari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2022-02-15</date><risdate>2022</risdate><volume>61</volume><issue>4</issue><spage>527</spage><epage>531</epage><pages>527-531</pages><artnum>7644-21</artnum><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>34433717</pmid><doi>10.2169/internalmedicine.7644-21</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0918-2918
ispartof	Internal Medicine, 2022/02/15, Vol.61(4), pp.527-531
issn	0918-2918 1349-7235
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8907760
source	Open Access: PubMed Central
subjects	Adrenal Cortex Hormones - therapeutic use Aged Antibodies, Monoclonal Biopsy Carcinoma, Non-Small-Cell Lung - pathology Case Report Chemoradiotherapy Chemoradiotherapy - methods Corticosteroids durvalumab Dyspnea Echocardiography EKG Heart diseases Humans Internal medicine irAE lung cancer Lung Neoplasms - drug therapy Magnetic resonance imaging Male Myocarditis Myocarditis - chemically induced Myocarditis - diagnosis Myocarditis - drug therapy Non-small cell lung carcinoma Respiration Small cell lung carcinoma Steroids
title	Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A36%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Durvalumab-associated%20Late-onset%20Myocarditis%20Successfully%20Treated%20with%20Corticosteroid%20Therapy&rft.jtitle=Internal%20Medicine&rft.au=Maetani,%20Tomoki&rft.date=2022-02-15&rft.volume=61&rft.issue=4&rft.spage=527&rft.epage=531&rft.pages=527-531&rft.artnum=7644-21&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.7644-21&rft_dat=%3Cproquest_pubme%3E2634884020%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c609t-c5b5b91cf4945a00251faa6e4706ae447ed82eb75c800e71103ae6b5269e50b23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2634884020&rft_id=info:pmid/34433717&rfr_iscdi=true